STERIS plc has announced its financial results for the fiscal year 2025, with revenue from continuing operations increasing by 6% to $5.5 billion, up from $5.1 billion in the previous year. The company also reported a constant currency organic revenue growth of 6% for the same period. For the fourth quarter alone, revenue grew by 4% to $1.5 billion compared to $1.4 billion in the fourth quarter of fiscal 2024, with constant currency organic revenue growth at 6%. In terms of earnings, the diluted EPS from continuing operations for the full fiscal year rose to $6.16, while the adjusted EPS per diluted share increased to $9.22. The company provided an optimistic outlook for fiscal 2026, reflecting confidence in continued growth. In the fourth quarter, the Healthcare segment saw reported revenue growth of 5%, reaching $1.1 billion. This was driven by a 13% increase in service revenue and 6% growth in consumable revenue, despite a 4% decline in capital equipment revenue. Healthcare operating income increased to $279.7 million, up from $245.2 million in the same period last year. The Applied Sterilization Technologies $(AST.UK)$ segment reported a 9% increase in fourth-quarter revenue, totaling $273.9 million compared to $250.9 million in the prior year quarter. This segment's operating income was $122.2 million, up from $114.2 million, due to improved volume and price, despite higher labor and energy costs. STERIS's President and CEO, Dan Carestio, attributed the record fiscal year to the company's diversified customer base and growth in global procedure volumes, expressing appreciation for the efforts of their global associates.